Amulti-gene assay for the clinically useful subclassification of ductal carcinoma in situ of the breast
Duke University is seeking a company interested in commercializing a novel and versatile method to distinguish “aggressive” from “indolent” low grade ductal in situ carcinomas (DCIS) breast cancer. Each year nearly 40,000 new cases DCIS are diagnosed accounting for 20% of all breast cancers. Today, nearly all DCIS are heavily treated although adjuvant treatment is not necessary in 80-90% low grade DCIS and in 50-70% high grade DCIS. The over-treatment of DCIS leads to adverse side effects for patients and unnecessary medical expenditure for the health care system. A method to accurately identify the DCIS patients who will not develop invasive carcinoma is needed.
Interested in this Technology?
Submit your interest below.